| growth inhibitors | Endogenous or exogenous substances which inhibit the normal growth of human and animal cells or micro-organisms, as distinguished from those affecting plant growth (= plant growth regulators). (12 Dec 1998) |
|---|---|
| phosphodiesterase inhibitors | Compounds which inhibit or antagonise the biosynthesis or actions of phosphodiesterases. (12 Dec 1998) |
| monoamine oxidase inhibitors | A chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines. Although mao inhibitors are probably as effective as tricyclic antidepressants in the treatment of major depression, the complex, sometimes severe, and often unpredictable interactions between mao inhibitors and many other drugs and food-derived amines make their medical use difficult and potentially hazardous. (12 Dec 1998) |
| platelet aggregation inhibitors | Drugs or agents which antagonise or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (12 Dec 1998) |
| cysteine proteinase inhibitors | Exogenous and endogenous compounds which inhibit cysteine proteinases. (12 Dec 1998) |
| protease inhibitors | Compounds which inhibit or antagonise biosynthesis or actions of proteases. (12 Dec 1998) |
| HIV integrase inhibitors | Inhibitors of HIV integrase, an enzyme required for integration of viral DNA into cellular DNA. (12 Dec 1998) |
| HIV protease inhibitors | Inhibitors of HIV protease, an enzyme required for production of proteins needed for viral assembly. (12 Dec 1998) |
| serine proteinase inhibitors | Exogenous or endogenous compounds which inhibit serine proteinases. (12 Dec 1998) |
| serotonin uptake inhibitors | Compounds that specifically inhibit the reuptake of serotonin in the brain. This increases the serotonin concentration in the synaptic cleft which then activates serotonin receptors to a greater extent. These agents have been used in treatment of depression, panic disorder, obsessive-compulsive behaviour, and alcoholism, as analgesics, and to treat obesity and bulimia. Many of the adrenergic uptake inhibitors also inhibit serotonin uptake; they are not included here. (12 Dec 1998) |
| hydroxymethylglutaryl-CoA reductase inhibitors | Compounds that inhibit hmg-CoA reductases. They have been shown to directly lower cholesterol synthesis. (12 Dec 1998) |
| neurotransmitter uptake inhibitors | Drugs that inhibit the transport of neurotransmitters into axon terminals or into storage vesicles within terminals. For many transmitters, uptake determines the time course of transmitter action so inhibiting uptake prolongs the activity of the transmitter. Blocking uptake may also deplete available transmitter stores. Many clinically important drugs are uptake inhibitors although the indirect reactions of the brain rather than the acute block of uptake itself is often responsible for the therapeutic effects. (12 Dec 1998) |
| nucleic acid synthesis inhibitors | Compounds that inhibit cell production of DNA or RNA. (12 Dec 1998) |
| dopamine uptake inhibitors | Drugs that block the transport of dopamine into axon terminals or into storage vesicles within terminals. most of the adrenergic uptake inhibitors also inhibit dopamine uptake. (12 Dec 1998) |
| integrase inhibitors | Compounds which inhibit or antagonise biosynthesis or actions of integrase. (12 Dec 1998) |